[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(10/2, FRI) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)

 [새책]『헌트-FcRn과 이뮤노반트』 사냥과 신약개발
[https://www.biospectator.com/news/view/29980](https://www.biospectator.com/news/view/29980)

 셀트리온, 시밀러 제품군 "북유럽서 잇단 입찰수주" 
[https://www.biospectator.com/news/view/29977](https://www.biospectator.com/news/view/29977)

 삼성바이오로직스, 국내외 제약바이오 4개 행사 참여
[https://www.biospectator.com/news/view/29970](https://www.biospectator.com/news/view/29970)

 ‘조경현 교수’ 오르텟, 5억弗 출범..”환자 중심 AI의료”
[https://www.biospectator.com/news/view/29951](https://www.biospectator.com/news/view/29951)

 암젠, 호라이즌 'ILT7 항체' 원판상루푸스 2상 "성공" 
[https://www.biospectator.com/news/view/29971](https://www.biospectator.com/news/view/29971)

 '노바티스 피인수' 어비디티, ARC서 AOC 변신과정은?
[https://www.biospectator.com/news/view/29790](https://www.biospectator.com/news/view/29790)

 사노피, 리제네론과 'next 듀피젠트' 합심 "80억弗 딜" 
[https://www.biospectator.com/news/view/29985](https://www.biospectator.com/news/view/29985)

 머크, ‘TL1A 항체’ HS 2b상 “긍정적 세부결과 발표"
[https://www.biospectator.com/news/view/29965](https://www.biospectator.com/news/view/29965)

 베링거, 'GLP-1/GCG' 3상 "체중 13.1%↓..기대 이하"
[https://www.biospectator.com/news/view/29988](https://www.biospectator.com/news/view/29988)

 에보뮨, 에이프릴 'IL-18' 아토피 2a상 "세부결과 공개"  
[https://www.biospectator.com/news/view/29986](https://www.biospectator.com/news/view/29986)

 에스엔바이오, ‘A, BBB’ 코스닥 기술성평가 통과
[https://www.biospectator.com/news/view/29991](https://www.biospectator.com/news/view/29991)

 휴온스, '장질환·비만' 약물 2종 비임상 "국제학회 발표" 
[https://www.biospectator.com/news/view/29987](https://www.biospectator.com/news/view/29987)

[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(10/2, FRI) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)